ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
BioSpace5h
AbbVie Continues Deal-Making Spree With $200M Nimble Buy
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...
BioSpace14h
Amyloid Hypothesis in Doubt as Newly Approved Drugs Hit Hurdles
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...